Kamala Harris

Joe Biden

Dean Phillips

Marianne Williamson

Donald Trump

Vivek Ramaswamy

Nikki Haley

Ron DeSantis

Cornel West

Robert F. Kennedy

2024 United States Presidential Election

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

tag:reuters.com,2019:binary_RC1D1ED65010-BASEIMAGE

RTÉ

Ireland

GSK shares up after settlement of 80,000 Zantac lawsuits

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US

Ad Fontes Media

All Sides

Media Bias/Fact Check

BBC News

Government of the United Kingdom

United Kingdom

Pharma giant GSK to pay $2.2 to settle Zantac lawsuits

GSK shares surged by the most in nearly two years in early trading after it said it will pay as much as $2.2bn (£1.7bn) to settle legal disputes over its claims that its Zantac drug caused cancer.]]>

The Telegraph

Press Holdings

David and Frederick Barclay

London

Greater London

England

GSK surges by £4.2bn after settling cancer claims - latest updates

Shares of GSK rose as much as 6.5% this morning after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the US that claimed its discontinued heartburn drug Zantac caused cancer.

Government of Ireland

On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company. Under these agreements, GSK will pay up to $2.2 billion to resolve the claims, contingent upon eligibility and participation criteria. In July, a Delaware judge dismissed a reque…

Benzinga

New York

United States

GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges

British pharmaceutical company GSK said on Wednesday that it has agreed to pay $2.3 billion to put an end to lawsuits in the United States alleging that its heartburn drug Zantac caused cancer.

"GSK today announced that it has reached agreements with 10 plaintiff firms who together represent 93 per cent (approximately 80,000) of the Zantac state court product liability cases pending against GSK," the company said in a statement.

WION

Invesco

Noida

Uttar Pradesh

India

Pharma company GSK agrees to pay $2.3bn in US settlements on lawsuits over Zantac cancer claims

Biopharma company GSK reached settlement agreements with 10 law firms representing multiple plaintiffs in cases related to the company allegedly selling carcinogenic drugs.
The settlement affects approximately 80,000 cases managed by these law firms, which represent 93 percent of lawsuits filed in the United States against GSK for its Zantac drug, an Oct. 9 company press release states. “Under these agreements, GSK will make an aggregate payment…

The Epoch Times

Epoch Media Group

Biopharma Company GSK to Settle 80,000 Zantac Cases for $2.2 Billion

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.

Medical Xpress

Zantac maker GSK says it reaches $2.3 bn settlement in US

GSK has agreed to pay $2.3 billion to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer.

Fortune

Chatchaval Jiaravanon

British pharma giant GSK strikes $2.3 billion deal to put an end to 80,000 U.S. lawsuits

The settlement covers roughly 80,000 cases, or 93% of the suits that were outstanding in state courts around the U.S.

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

GSK to pay up to $2.2 billion to settle most Zantac lawsuits over claims the heartburn pill causes cancer

The British drug maker GSK said on Wednesday that it would pay up to $2.2 billion to settle most of the lawsuits filed against it by people who claim that they developed cancer after taking a now-discontinued blockbuster heartburn drug commonly known by the brand name Zantac. GSK, which developed the drug decades ago and sold a version of it until 2017, did not admit liability in settling the cases. The evidence is mixed on whether the drug elev…

DNyuz

Zantac’s Developer Settles Lawsuits Claiming Cancer Link

Cancer

Business

US Economy

Pfizer

Health

Business Times

AlKhaleej Today

aboutlawsuits.com

MoneyWeek

News.law

Macau Business

regionalmedianews.com

sfdailyrecord.com

abbonews.com

The Business Times

UK firm GSK to pay $2.2bn over Zantac cancer claims

Arutz Sheva

Maariv Online

Jerusalem Post

israelhayom.co.il

Anadolu Ajansı

Israel-Hamas Conflict

Election Day

Fox News

US Politics

Republican Party

US Crime

Netflix

US Immigration

Volleyball

Abortion

UK firm GSK to pay $2.2bn over Zantac cancer claims

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics